Medindia

X

Amylin Pharmaceuticals Announces Online Summit

Tuesday, June 8, 2010 General News J E 4
Advertisement


SAN DIEGO, June 7, 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that it is hosting an online summit focusing on perspectives within the diabetes community and information from topics that will be discussed at the American Diabetes Association's (ADA's) upcoming 70th Annual Scientific Sessions in Orlando, FL.

Through the Online Summit, Amylin will digitally aggregate perspectives from leaders throughout the diabetes community, providing a resource to help advance understanding of the key issues facing the field, and viewpoints on the latest innovations and treatment strategies that will shape the future of diabetes care. Amylin is hosting the Online Summit in the weeks leading up to, and throughout the duration of, the ADA's Scientific Sessions. Additional "wrap-up" perspectives will be posted in the weeks following the conference.

Online perspectives will be updated multiple times per week with fresh content from myriad contributors, spanning roles in clinical care, research, health policy, patient advocacy and other interests. Content from the Online Summit will be made available, and archived for approximately 90 days, on Amylin's corporate Web site at www.amylin.com.

The first entry, posted today, is an introduction to the Online Summit by David Maggs, MD, vice president, R&D Strategic Relations at Amylin Pharmaceuticals. Additional entries will be posted regularly throughout the next two months.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.

SOURCE Amylin Pharmaceuticals, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Teen Voices Central to the Above the Influence Cam...
S
DURECT Corporation Invites You to Join a Conferenc...